Cargando…

Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials

BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Guodong, Long, Jianhai, Luo, Yuan, Wang, Yongan, Zewu, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440140/
https://www.ncbi.nlm.nih.gov/pubmed/28514303
http://dx.doi.org/10.1097/MD.0000000000006875
_version_ 1783238020560846848
author Lin, Guodong
Long, Jianhai
Luo, Yuan
Wang, Yongan
Zewu, Qiu
author_facet Lin, Guodong
Long, Jianhai
Luo, Yuan
Wang, Yongan
Zewu, Qiu
author_sort Lin, Guodong
collection PubMed
description BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely used in clinical practice; however, its effect remains uncertain. Accordingly, the purpose of this meta-analysis was to evaluate the efficacy of CVVH in the treatment of PQ poisoning. METHODS: We searched for relevant trials using PubMed, Embase, the Cochrane Library, and 3 Chinese databases, the Chinese BioMedical Literature Database, National Knowledge Infrastructure Database, and Wanfang Database. We included all qualified randomized controlled trials (RCTs) of CVVH treatment for patients with PQ poisoning. The primary outcome was mortality, while the secondary outcomes included the survival time and constituent ratios of death due to respiratory failure and circulatory failure. RESULTS: Three RCTs involving 290 patients were included. The mortality rates of the intervention and control groups were 57.9% and 61.0%, respectively. Pooled analysis demonstrated no significant difference in mortality between the CVVH treatment and control groups (risk ratio [RR] 0.94, 95% confidence interval [CI]: 0.78–1.15, P = .56), with a low level of heterogeneity (X(2) = 1.75, I(2) = 0%). However, the CVVH group was associated with a longer survival time compared to the control group (weighted mean difference 1.73, 95% CI: 0.56–2.90, P = .004). Respiratory failure as the cause of death was more common in the CVVH group, as compared with the control group (RR 1.66, 95% CI: 1.24–2.23, P = .0008), whereas patients in the control group were more likely to die from circulatory failure than in the CVVH group (RR 0.56, 95% CI: 0.40–0.81, P = .002). CONCLUSION: Although CVVH treatment might not noticeably reduce mortality for patients with PQ poisoning, it can prolong the survival time of the patients and improve the stability of the circulatory system, thereby enabling further treatment.
format Online
Article
Text
id pubmed-5440140
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54401402017-05-25 Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials Lin, Guodong Long, Jianhai Luo, Yuan Wang, Yongan Zewu, Qiu Medicine (Baltimore) 3900 BACKGROUND: Paraquat (PQ) poisoning is a widespread occurrence, especially in underdeveloped areas. The treatment of PQ poisoning has always been difficult, and there is currently no definite effective treatment. Continuous venovenous hemofiltration (CVVH) treatment for PQ poisoning has been widely used in clinical practice; however, its effect remains uncertain. Accordingly, the purpose of this meta-analysis was to evaluate the efficacy of CVVH in the treatment of PQ poisoning. METHODS: We searched for relevant trials using PubMed, Embase, the Cochrane Library, and 3 Chinese databases, the Chinese BioMedical Literature Database, National Knowledge Infrastructure Database, and Wanfang Database. We included all qualified randomized controlled trials (RCTs) of CVVH treatment for patients with PQ poisoning. The primary outcome was mortality, while the secondary outcomes included the survival time and constituent ratios of death due to respiratory failure and circulatory failure. RESULTS: Three RCTs involving 290 patients were included. The mortality rates of the intervention and control groups were 57.9% and 61.0%, respectively. Pooled analysis demonstrated no significant difference in mortality between the CVVH treatment and control groups (risk ratio [RR] 0.94, 95% confidence interval [CI]: 0.78–1.15, P = .56), with a low level of heterogeneity (X(2) = 1.75, I(2) = 0%). However, the CVVH group was associated with a longer survival time compared to the control group (weighted mean difference 1.73, 95% CI: 0.56–2.90, P = .004). Respiratory failure as the cause of death was more common in the CVVH group, as compared with the control group (RR 1.66, 95% CI: 1.24–2.23, P = .0008), whereas patients in the control group were more likely to die from circulatory failure than in the CVVH group (RR 0.56, 95% CI: 0.40–0.81, P = .002). CONCLUSION: Although CVVH treatment might not noticeably reduce mortality for patients with PQ poisoning, it can prolong the survival time of the patients and improve the stability of the circulatory system, thereby enabling further treatment. Wolters Kluwer Health 2017-05-19 /pmc/articles/PMC5440140/ /pubmed/28514303 http://dx.doi.org/10.1097/MD.0000000000006875 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 3900
Lin, Guodong
Long, Jianhai
Luo, Yuan
Wang, Yongan
Zewu, Qiu
Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title_full Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title_fullStr Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title_full_unstemmed Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title_short Continuous venovenous hemofiltration in the management of paraquat poisoning: A meta-analysis of randomized controlled trials
title_sort continuous venovenous hemofiltration in the management of paraquat poisoning: a meta-analysis of randomized controlled trials
topic 3900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440140/
https://www.ncbi.nlm.nih.gov/pubmed/28514303
http://dx.doi.org/10.1097/MD.0000000000006875
work_keys_str_mv AT linguodong continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials
AT longjianhai continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials
AT luoyuan continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials
AT wangyongan continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials
AT zewuqiu continuousvenovenoushemofiltrationinthemanagementofparaquatpoisoningametaanalysisofrandomizedcontrolledtrials